Akums Drugs secures a patent for a novel Hydroxyurea formulation, promising affordable treatment for Sickle Cell Disease and enhancing patient care.
Akums Drugs and Pharmaceuticals has announced that it has received a patent from the Indian patent office for an innovative formulation aimed at treating Sickle Cell Disease (SCD). This new oral suspension of Hydroxyurea is designed to be stable at room temperature, making it easier for patients to manage this genetic blood disorder that causes ...